Severe thrombocytopenia in a patient with COVID-19

Eliel Nham; Jae Hoon Ko; Byeong Ho Jeong; Kyungmin Huh; Sun Young Cho; Cheol In Kang; Doo Ryeon Chung; Kyong Ran Peck

doi:10.3947/ic.2020.52.3.410

Severe thrombocytopenia in a patient with COVID-19

Department of Internal Medicine

Sungkyunkwan University

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Coronavirus disease 2019 (COVID-19) outbreak is spreading rapidly all over the world, being a major threat to public health. Since clinical feature of COVID-19 has not been fully evaluated yet, empirical antibacterial agents are frequently combined for the treatment of COVID-19 in addition to antiviral agents, concerning co-existing bacterial pathogens. We experienced a case of severe thrombocytopenia with epistaxis and petechiae, while treating a COVID-19 patient with ceftriaxone, levofloxacin, and lopinavir/ritonavir. The platelet count decreased to 2,000/mm³ and recovered after discontinuation of the three suspected drugs. In treating a potentially fatal emerging infectious disease, empirical and/or experimental approach would be unavoidable. However, the present case suggests that the possibility of adverse effects caused by polypharmacy should also be carefully considered.

Original language	English
Pages (from-to)	410-414
Number of pages	5
Journal	Infection and Chemotherapy
Volume	52
Issue number	3
DOIs	https://doi.org/10.3947/ic.2020.52.3.410
State	Published - Sep 2020

Keywords

COVID-19
Ceftriaxone
Levofloxacin
Lopinavir/ritonavir
Thrombocytopenia

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3947/ic.2020.52.3.410

Cite this

@article{e5e8d41e558245e2936b49287f90c5c2,

title = "Severe thrombocytopenia in a patient with COVID-19",

abstract = "Coronavirus disease 2019 (COVID-19) outbreak is spreading rapidly all over the world, being a major threat to public health. Since clinical feature of COVID-19 has not been fully evaluated yet, empirical antibacterial agents are frequently combined for the treatment of COVID-19 in addition to antiviral agents, concerning co-existing bacterial pathogens. We experienced a case of severe thrombocytopenia with epistaxis and petechiae, while treating a COVID-19 patient with ceftriaxone, levofloxacin, and lopinavir/ritonavir. The platelet count decreased to 2,000/mm3 and recovered after discontinuation of the three suspected drugs. In treating a potentially fatal emerging infectious disease, empirical and/or experimental approach would be unavoidable. However, the present case suggests that the possibility of adverse effects caused by polypharmacy should also be carefully considered.",

keywords = "COVID-19, Ceftriaxone, Levofloxacin, Lopinavir/ritonavir, Thrombocytopenia",

author = "Eliel Nham and Ko, \{Jae Hoon\} and Jeong, \{Byeong Ho\} and Kyungmin Huh and Cho, \{Sun Young\} and Kang, \{Cheol In\} and Chung, \{Doo Ryeon\} and Peck, \{Kyong Ran\}",

note = "Publisher Copyright: {\textcopyright} 2020 by The Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, and The Korean Society for AIDS This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",

year = "2020",

month = sep,

doi = "10.3947/ic.2020.52.3.410",

language = "English",

volume = "52",

pages = "410--414",

journal = "Infection and Chemotherapy",

issn = "2093-2340",

publisher = "Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, Korean Society for AIDS, Korean Society of Pediatric Infectious Diseases",

number = "3",

}

TY - JOUR

T1 - Severe thrombocytopenia in a patient with COVID-19

AU - Nham, Eliel

AU - Ko, Jae Hoon

AU - Jeong, Byeong Ho

AU - Huh, Kyungmin

AU - Cho, Sun Young

AU - Kang, Cheol In

AU - Chung, Doo Ryeon

AU - Peck, Kyong Ran

N1 - Publisher Copyright: © 2020 by The Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, and The Korean Society for AIDS This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PY - 2020/9

Y1 - 2020/9

N2 - Coronavirus disease 2019 (COVID-19) outbreak is spreading rapidly all over the world, being a major threat to public health. Since clinical feature of COVID-19 has not been fully evaluated yet, empirical antibacterial agents are frequently combined for the treatment of COVID-19 in addition to antiviral agents, concerning co-existing bacterial pathogens. We experienced a case of severe thrombocytopenia with epistaxis and petechiae, while treating a COVID-19 patient with ceftriaxone, levofloxacin, and lopinavir/ritonavir. The platelet count decreased to 2,000/mm3 and recovered after discontinuation of the three suspected drugs. In treating a potentially fatal emerging infectious disease, empirical and/or experimental approach would be unavoidable. However, the present case suggests that the possibility of adverse effects caused by polypharmacy should also be carefully considered.

AB - Coronavirus disease 2019 (COVID-19) outbreak is spreading rapidly all over the world, being a major threat to public health. Since clinical feature of COVID-19 has not been fully evaluated yet, empirical antibacterial agents are frequently combined for the treatment of COVID-19 in addition to antiviral agents, concerning co-existing bacterial pathogens. We experienced a case of severe thrombocytopenia with epistaxis and petechiae, while treating a COVID-19 patient with ceftriaxone, levofloxacin, and lopinavir/ritonavir. The platelet count decreased to 2,000/mm3 and recovered after discontinuation of the three suspected drugs. In treating a potentially fatal emerging infectious disease, empirical and/or experimental approach would be unavoidable. However, the present case suggests that the possibility of adverse effects caused by polypharmacy should also be carefully considered.

KW - COVID-19

KW - Ceftriaxone

KW - Levofloxacin

KW - Lopinavir/ritonavir

KW - Thrombocytopenia

UR - https://www.scopus.com/pages/publications/85087436335

U2 - 10.3947/ic.2020.52.3.410

DO - 10.3947/ic.2020.52.3.410

M3 - Article

AN - SCOPUS:85087436335

SN - 2093-2340

VL - 52

SP - 410

EP - 414

JO - Infection and Chemotherapy

JF - Infection and Chemotherapy

IS - 3

ER -

Severe thrombocytopenia in a patient with COVID-19

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this